Position in AZN
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$159,501,517
+$62,381,318 QoQ
Shares Held
841,164
+70.8% QoQ
Ownership
0.054%
of shares outstanding
% of Portfolio
0.19%
of 13F equity value
Holder Rank
#105
of 1,459 holders
Holding Since
Dec 2021
3 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in AZN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $2,303,425,127 across 13 Drug Manufacturers - General names. AZN ranks #4 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
2,989,537 | $759,252,709 | |
| 2 | ABBV |
AbbVie Inc.
|
2,990,512 | $752,532,439 | |
| 3 | LLY |
ELI LILLY & Co
|
334,637 | $401,373,688 | |
| 4 | AZN |
Astrazeneca PLC
This page
|
841,164 | $159,501,517 | |
| 5 | NVO |
Novo Nordisk A S
|
1,707,104 | $81,838,564 | |
| 6 | NVS |
Novartis AG
|
330,061 | $51,727,159 | |
| 7 | AMGN |
Amgen Inc
|
99,402 | $35,995,452 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
204,677 | $25,858,892 |
All Filings in AZN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $159,501,517 | 841,164 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $97,120,199 | 492,446 | Shares | Other | 2026-05-15 | |
| 2021-12-31 | $30,930 | 531 | Shares | Other | 2022-02-14 | |
| No filing history on record for this holder in this stock. | ||||||